Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

• Status: Completed
• Trial end date: 2017-09-08
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the investigators was to delineate the efficacy and safety of Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) plus ribavirin (RBV) on chronic HCV GT4 Egyptian naïve patients

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beni-Suef University
• Treatments: Ribavirin

Criteria

Inclusion Criteria:

Treatment-naïve patients with HCV GT4 with plasma HCV RNA level >10,000 IU/ml

Exclusion Criteria:

• Hepatitis of non-HCV cause

• Coinfection with other than HCV GT4

• Poorly controlled diabetics (HbA1C >8) patients

• a history of extra-hepatocellular malignancy in the last 5 years

• Major severe illness such as congestive heart failure, respiratory failure, evidence of hepatic decompensation.

• Laboratory and blood picture abnormalities such as anemia (hemoglobin concentration of 10g/dL, international normalized ratio (INR) of > 2.3, serum total bilirubin concentration of >3.0 mg/dL.